August 26, 2016 8:26am
A ‘scorecard’ of public stem, cell, gene and regenerative therapy’s companies …
The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position for a better snapshot!
By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
http://www.regmedinvestors.com/articles/9257